Preferred Label : acalabrutinib;

Obsolete resource : false;

UNII : I42748ELQW;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3427072/fr/calquence-acalabrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
del(17p) Negative
TP53 Gene Mutation Negative
adult
Acalabrutinib/Obinutuzumab Regimen
administration, oral
acalabrutinib
Loss of Chromosome 17p
TP53 Gene Mutation
evaluation of the transparency committee
acalabrutinib
leukemia, lymphocytic, chronic, B-Cell

---
https://www.has-sante.fr/jcms/p_3448231/fr/calquence-acalabrutinib-leucemie-lymphoide-chronique-llc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
tablets
antineoplastic agents
protein kinase inhibitors
acalabrutinib
Acalabrutinib/Obinutuzumab Regimen
evaluation of the transparency committee
leukemia, lymphocytic, chronic, B-Cell
Chronic lymphocytic leukemia
acalabrutinib

---
https://www.has-sante.fr/jcms/p_3310174/fr/calquence-100-mg-acalabrutinib
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
administration, oral
adult
leukemia, lymphocytic, chronic, B-Cell
antineoplastic agents
BTK Inhibitor
protein kinase inhibitors
acalabrutinib
Recurrent Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
continuity of patient care
acalabrutinib
evaluation of the transparency committee
acalabrutinib

---
https://www.has-sante.fr/jcms/p_3265516/fr/calquence-acalabrutinib
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
acalabrutinib
acalabrutinib
administration, oral
protein kinase inhibitors
adult
leukemia, lymphocytic, chronic, B-Cell
evaluation of the transparency committee
benzamides
pyrazines

---
https://www.ema.europa.eu/en/medicines/human/EPAR/calquence
2020
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
acalabrutinib
acalabrutinib
antineoplastic agents
antineoplastic agents
adult
leukemia, lymphocytic, chronic, B-Cell
antineoplastic combined chemotherapy protocols
obinutuzumab
administration, oral
Agammaglobulinaemia Tyrosine Kinase
protein kinase inhibitors
protein kinase inhibitors
acalabrutinib
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
Tyrosine Kinase Inhibitors
benzamides
pyrazines
benzamides
pyrazines
antibodies, monoclonal, humanized

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.